Your Health, We Care

Home > Photo Wall > Honor and qualification

Production approval for Giletitinib

Release date: 2024-07-10 14:45:22     Recommended: 127

07L0995_23 吉瑞替尼 批文_00.jpg

It is an FMS like tyrosine kinase 3 (FLT3) inhibitor with inhibitory effects on FLT3 mutations, used for the treatment of adult patients with recurrent or refractory acute myeloid leukemia (AML) detected by fully validated detection methods carrying FMS like tyrosine kinase 3 (FLT3) mutations.

Company News

Research News

Drug news